Gram stain–guided therapy safely cut broad-spectrum antibiotics in patients with ventilator-associated pneumonia.
National Football League (NFL) games played with fans in the 2020 season, with mask mandates and physical distancing in place, had no effect on COVID-19 infections in the surrounding county, suggests a new study in the Proceedings of the National Academy of Sciences (PNAS).
The introduction of procalcitonin (PCT) testing at UK hospitals during the first wave of the COVID-19 pandemic was associated with an immediate but not sustained decline in antibiotic prescribing, researchers reported today in the Journal of Antimicrobial Chemotherapy.
A new paper in Nature Communications describes the use of a pre-adapted bacteriophage in combination with antibiotics to treat a patient with a fracture-related, pandrug-resistant (PDR) Klebsiella pneumoniae infection.
A new review of the antibiotic development pipeline finds that there are relatively few clinically differentiated products in late-stage clinical development, especially against critical, multidrug-resistant pathogens, an international team of researchers reported yesterday in Antimicrobial Agents and Chemotherapy.
A study conducted at a large teaching hospital in Tokyo found that most tests used to diagnose invasive fungal disease were inappropriate, Japanese researchers reported yesterday in Open Forum Infectious Diseases.
Use of a rapid diagnostic test in patients with bloodstream infections (BSIs) was associated with shorter times to optimal antibiotic therapy and antibiotic de-escalation, researchers reported yesterday in Clinical Infectious Diseases.
Positive pneumococcal urinary antigen testing (PUAT) results among patients hospitalized with community-acquired pneumonia (CAP) was associated with earlier time to de-escalation of antibiotics, according to a single-center study published last week in Open Forum Infectious Diseases.
A clinical trial in the Netherlands found that an antimicrobial stewardship intervention safely reduced broad-spectrum antibiotic use in patients hospitalized with moderately severe pneumonia, Dutch researchers reported yesterday in The Lancet Infectious Diseases.
Diagnostics company OpGen announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market a new rapid molecular diagnostic tool that could aid in treating antibiotic-resistant or non-susceptible infections.
